Table 1 Baseline characteristics of IVMP recipients and Tacrolimus recipients
IVMP | Tacrolimus | p value | |
|---|---|---|---|
Age (years) (median [IQR]) | 20 (16, 24.5) | 23.5 (16, 32) | 0.230 |
Male/female (n, %) | 14 (48.3%)/15 (51.7%) | 6 (21.4%)/22 (78.6%) | 0.052 |
Age at onset (years) (median [IQR]) | 8 (3.5, 14) | 16 (7.3, 26.8) | 0.003* |
Course of disease (months) (median [IQR]) | 120 (66, 186) | 42 (16, 132) | 0.016* |
Antibody status | |||
AChR-Ab positivity (n, %) | 21 (72.4%) | 18 (64.3%) | 0.509 |
MuSK-Ab positivity (n, %) | 0 | 2 (7.1%) | 0.237 |
Seronegative (n, %) | 8 (27.6%) | 9 (32.1%) | 0.707 |
AChR-Ab titer (nmol/L) (median [IQR]) | 0.87 (0.52, 3.22) | 1.32 (0.40, 3.34) | 0.742 |
Thymus | |||
Thymic hyperplasia (n, %) | 2 (6.9%) | 4 (14.3%) | 0.633 |
Thymoma (n, %) | 2 (6.9%) | 2 (7.1%) | 1.000 |
Thymectomy before treatment (n, %) | 2 (6.9%) | 4 (14.3%) | 0.633 |
Autoimmune thyroid diseases (n, %) | 8 (27.6%) | 14 (50.0%) | 0.082 |
Onset symptoms | |||
Ptosis (unilateral) (n, %) | 18 (62.1%) | 17 (60.7%) | 0.518 |
Ptosis (bilateral) (n, %) | 11 (37.9%) | 9 (32.1%) | |
Diplopia (n, %) | 13 (44.8%) | 14 (50.0%) | 0.696 |
QMG score at baseline (median [IQR]) | |||
Ocular QMG score | 5 (3, 7.5) | 4.5 (3, 5.75) | 0.232 |
QMG score for diplopia | 3 (0, 3) | 2.5 (0, 3) | 0.421 |
QMG score for ptosis | 3 (1, 3) | 2.5 (1, 3) | 0.513 |
QMG score for eyelid closure | 1 (0, 2) | 1 (0, 1) | 0.192 |